Download FREE Sample
The global molecular infectious disease testing market size is set to witness a growth rate of 13% in the next 5 years. Rising burden of infectious diseases, demand for rapid accurate results, technological advancements in molecular diagnostics, and increased R&D funding and public health support are some of the key factors driving the molecular infectious disease testing market.
Molecular infectious disease testing refers to various approaches that are employed to identify and characterize infectious agents (viruses/bacteria, etc.) based on their genotype. Molecular infectious disease testing typically employs polymerase chain reaction (PCR), isothermal amplification methods and/or next generation sequencing (NGS) among others to provide the highest level of sensitivity and specificity. With the use of these molecular diagnostic techniques, clinicians can identify the pathogens causing illness and potentially develop a treatment plan that includes the appropriate use of antimicrobial agents. Molecular testing is also used to provide very early identification of infectious diseases; differentiation of one pathogen from another; and supportive decision-making.
Rising burden of infectious diseases to propel market demand
A major factor that is driving the growth of the molecular infectious disease testing market is the increase in the burden of infectious disease throughout the world as healthcare systems attempt to meet the increasing demands for the ability to detect, manage, and contain all types and forms of infections as rapidly and accurately as possible. Infectious diseases remain a leading cause of global mortality, with tuberculosis causing 10.7 million cases and 1.23 million deaths in 2024, while malaria recorded 282 million cases in 2024 (up 3% from 2023) and 610,000 deaths, compared to 598,000 deaths in 2023. Dengue incidence has surged with reported cases rising from 505,430 in 2000 to 14.6 million in 2024, highlighting the growing global infectious disease burden (Source: WHO). Urbanization, globalization, climate change, antimicrobial resistance, and ageing populations are collectively driving a rise in respiratory infections, sexually transmitted diseases, gastrointestinal diseases, tuberculosis, hepatitis, HIV, and vector-borne diseases worldwide. At the same time, the continuous emergence and re-emergence of pathogenic organisms is increasing the frequency and complexity of disease outbreaks. This has created a growing need for rapid-response and adaptable diagnostic solutions capable of addressing new and evolving disease threats as they arise. The technology behind molecular testing directly addresses these current and anticipated clinical needs by enabling the early and precise detection and characterization of pathogenic organisms, even at the lowest levels of concentration, often at an earlier stage than the onset of severe clinical symptoms or when rapid or substantial transmission occurs. As the overall burden of disease increases, the reliance on clinicians and public health authorities for the distinction between viral or bacterial infections, the identification of co-infections, and for the selection of appropriate targeted therapy has increased, which has created a continual demand for molecular testing within hospitals, diagnostic laboratories, and public health agencies. There is an increasing burden placed on healthcare systems because of the increase in the number of patients infected by a variety of infectious diseases. In turn, the greater the number of infections, the greater the financial burden associated with the delayed or incorrect diagnosis of infectious diseases. To decrease the financial burden on healthcare systems due to delayed diagnosis of diseases or delaying treatment of patients, healthcare providers have started to utilize molecular diagnostic tests that assist in determining the appropriate course of treatment for patients more quickly, resulting in lower financial costs associated with treating patients and fewer hospital days spent by patients receiving treatment for their infections. The rising rate of infections, coupled with the need for outbreak preparedness and controlling outbreaks, has placed an increasing emphasis on disease surveillance from the public health perspective. Molecular tests allow for the rapid identification of the causative agents of infectious diseases during an outbreak, support large-scale screening programs, and enable tracking of disease spread and mutation patterns. As a result, governments and other global health organizations are continuing to invest in the development of the capacity of molecular diagnostics as an integral component of the management of infectious disease outbreaks. The increasing burden of infectious diseases has been and will continue to be a growing factor promoting long-term growth for the molecular-based testing market for infectious diseases. As the world moves to post-pandemic awareness, greater need for routine screening and higher expectations from healthcare professionals and patients regarding speed and accuracy of laboratory-grade testing will increase the market for molecular-based testing for infectious diseases.
To learn more about this report, download the PDF brochure
Growth in point-of-care molecular solutions A key growth opportunity
The rise of point-of-care molecular solutions provides a lucrative opportunity in the global molecular infectious disease testing market due to the impact these technologies have on where and how diagnostic tests are done. In contrast to traditional approaches to molecular diagnostic testing which is typically performed in centrally located laboratories with dedicated staff and complex equipment, a POC molecular test can provide laboratory level sensitivity and specificity at or close to the time of patient interaction, allowing for prompt clinical decision-making and increased access to quality testing. Emergency departments, outpatient clinics and primary care practices have experienced growing demand for prompt diagnostic testing, which supports the use of POC molecular platforms. The need for immediate treatment decisions when dealing with infectious diseases creates the risk of delays in diagnosis resulting in progressed disease state, greater disease transmission and increased healthcare costs. As an alternative solution to this issue, the availability of results from POC molecular testing within minutes to one hour enables healthcare providers to begin effective treatment during the same encounter. The value of this feature in dealing with respiratory infections, sexually transmitted infections, and hospital-acquired infections is substantial. POC molecular testing also offers many options for decentralized and resource-limited environments, such as rural healthcare facilities, community-based clinics, or field-based public health programs, where centralized molecular laboratories are often absent. Compact and automated point-of-care systems with minimal preparation requirements support consistent and reliable testing capabilities in these settings, thereby increasing the potential for detecting and diagnosing disease in areas with high incidences of infectious disease. In addition, this will expand the scope of the molecular diagnostic market, to reach areas traditionally underserved by the laboratory network system. From a public health and health system viewpoint, the growth of POC molecular solutions advances and enhances outbreak management and infection control. Point-of-care testing performed in a rapid, onsite manner, facilitates early identification of cases, speedy decisions on isolation, and rapid initiation of treatment, thus slowing disease spread. Through increased awareness about POC molecular testing as a vital tool for epidemic preparedness, as well as facilitating routine surveillance, governments and health agencies are increasingly promoting the adoption of POC molecular diagnostics. POC molecular platforms provide a unique, opportunity for manufacturers of consumables and cartridges, thereby simplifying the operation of end-users, and increasing the opportunities for manufacturers to generate recurring revenues. As technological advances lower the cost, increase the ease of use, and extend the multiplexing capability of POC molecular solutions, these technologies will emerge as an integral growth engine of the molecular infectious disease testing market; simultaneously, fulfilling unmet clinical needs and facilitating the broadest, fastest, and most equitable access to advanced diagnostic technologies.Growth strategies adopted by players to establish their foothold in the market
Players operating in this market are adopting various growth strategies such as new product launches, strategic partnerships and collaborations, and acquisitions to garner market share. For instance,- In October 2025, Sysmex entered into a strategic alliance with QIAGEN for the exclusive distribution and supply of molecular diagnostic instruments and reagents for infectious diseases and oncology in Japan. The partnership strengthened Sysmexs clinical diagnostics portfolio by expanding access to QIAGENs molecular tests, including tuberculosis diagnostics, while accelerating adoption across Japanese medical institut and testing centers
- In June 2025, bioMrieux acquired the assets of Day Zero Diagnostics to strengthen its next-generation sequencing capabilities in infectious disease diagnostics and antimicrobial resistance detection. The acquisition enhanced bioMrieuxs R&D pipeline with rapid sequencing-based ID/AST solutions
- In February 2023, Thermo Fisher Scientific launched Applied Biosystems TaqPath real-time PCR kits in India for detection of infectious diseases including TB, HIV, HBV, and HCV, following CDSCO approval and local manufacturing in partnership with Mylab Discovery Solutions. The launch strengthened Indias molecular diagnostics ecosystem by offering clinically validated, high-sensitivity PCR solutions and an end-to-end qPCR workflow for clinical laboratories and diagnostic development
To learn more about this report, download the PDF brochure
Product and Service Segment Outlook
Reagents and kits represent the largest segment in the molecular infectious disease testing market due to their routine testing, high volume of tests conducted, and continuous demand from hospitals and diagnostic laboratories. Diagnostic tests require consumables, including reagents, primer sets, probe sets, and assay kits; this ensures that revenue generated from the sale of these consumables is based upon predictable volumes of purchased consumables compared to the sale of instrumentation which typically has a one-time purchase. Services and software constitute the fastest-growing segment, supported by increasing adoption of advanced data analysis, bioinformatics, laboratory automation, and connectivity solutions. Growth is further fueled by rising use of multiplex assays, next-generation sequencing, and the need for efficient workflow integration, data interpretation, and regulatory-compliant reporting across diagnostic settings.Regional Outlook: North America expected to hold a major share in the molecular infectious disease testing market
North America represents the largest regional segment in the molecular infectious disease testing market, with an advanced healthcare system, an established market for molecular diagnostics, strong reimbursement policies, and numerous leading companies that provide a complete portfolio of service products. The region also benefits from high testing volumes, robust public health programs, and significant R&D investments. Asia Pacific (APAC) is the fastest-growing region, driven by a large patient population, rising infectious disease burden, expanding healthcare infrastructure, and increasing government investments in diagnostics. Rapid urbanization, improving laboratory capacity, growing awareness, and local manufacturing initiatives further accelerate molecular testing adoption across emerging APAC economies.Competitive Landscape Analysis
The global molecular infectious disease testing market is marked by the presence of established and emerging market players such as Danaher Corporation (US); F. Hoffmann-La Roche Ltd (Switzerland); BIOMERIEUX (France); Abbott (US); Thermo Fisher Scientific Inc. (US); QIAGEN (Germany); Hologic, Inc. (US); Becton, Dickinson and Company (BD) (US); Siemens Healthineers AG (Germany); and Seegene Inc. (S. Korea); among others. Some of the key strategies adopted by market players include product launches, strategic partnerships and collaborations, and acquisitions.
Get a sample report for competitive landscape analysis
Report Scope
| Report Metric | Details |
| Base Year Considered | 2025 |
| Historical Data | 2024 2025 |
| Forecast Period | 2026 2031 |
| Growth Rate | 13% |
| Segment Scope | Product and Service, Type, Technology, Application, End User |
| Regional Scope |
|
| Market Drivers |
|
| Attractive Opportunities |
|
| Key Companies Mapped | Danaher Corporation (US); F. Hoffmann-La Roche Ltd (Switzerland); BIOMERIEUX (France); Abbott (US); Thermo Fisher Scientific Inc. (US); QIAGEN (Germany); Hologic, Inc. (US); Becton, Dickinson and Company (BD) (US); Siemens Healthineers AG (Germany); and Seegene Inc. (S. Korea) among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Molecular Infectious Disease Testing Market Segmentation
This report by Medi-Tech Insights provides thesize of the global molecular infectious disease testing market at theregional- and country-level from 2024 to 2031. The report further segments the market based on product and service, type, technology, application, and end user.Market Size & Forecast (2024-2031), By Product and Service, USD Billion
- Reagents and Kits
- Instruments
- Services and Software
Market Size & Forecast (2024-2031), By Type, USD Billion
- Singleplex Testing
- Multiplex Testing
Market Size & Forecast (2024-2031), By Technology, USD Billion
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification
- DNA Sequencing and Next-generation Sequencing (NGS)
- In Situ Hybridization
- DNA Microarrays
- Other Technologies
Market Size & Forecast (2024-2031), By Application, USD Billion
- Respiratory Infectious Diseases
- Gastrointestinal Infectious Diseases
- Sexually Transmitted Infections (STIs)
- Vector-borne Diseases
- Hospital-acquired Infections
- Other Applications
Market Size & Forecast (2024-2031), By End User, USD Billion
- Diagnostic Laboratories
- Hospitals and Clinics
- Other End Users
Market Size & Forecast (2024-2031), By Region, USD Billion
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
